Demografi, Respon Terapi dan Survival rate Pasien Kanker Serviks Stadium III-IVA yang Mendapat Kemoterapi Dilanjutkan Radioterapi
Downloads
Tujuan: Mengetahui demografi pasien kanker serviks III-IVa, respon terapi dan survival rate pasien kanker serviks stadium III-IVA yang mendapat kemoterapi dilanjutkan radioterapi di RSUD Dr. Soetomo Surabaya tahun 2011-2013.
Bahan dan Metode: Penelitian ini adalah penelitian deskriptif rektrospektif dengan menggunakan rekam medis Poli Onkologi Kandungan dan SMF/Instalasi Radioterapi RSUD Dr.Soetomo. Subyek penelitian adalah pasien kanker serviks III-IVA yang mendapat kemoterapi dilanjutkan radioterapi mulai Januari 2011 sampai Desember 2013. Analisis statistika pada penelitian ini menggunakan analisis deskriptif dan analisis survival meng-gunakan metode Kaplan Meier.
Hasil: Selama tahun 2011-2013 didapatkan kunjungan pasien baru kanker serviks III-IVA sebanyak 648 pasien. Jumlah pasien kanker serviks IIIA sebanyak 48 kasus, stadium IIIB sebanyak 594 kasus dan stadium IVA sebanyak 6 kasus. Jumlah pasien kanker serviks III–IVA yang mendapat kemoterapi dilanjutkan radioterapi selama tahun 2011-2013 sebanyak 77 pasien. Pasien kanker serviks stadium IIIA sebanyak 8 pasien, stadium IIIB sebanyak 69 pasien. Tidak ada pasien kanker serviks stadium IVA yang mendapat kemoterapi dilanjutkan radioterapi. Respon terapi komplet sebesar 88,3% dan respon terapi inkomplet sebesar 11,7%. Analisis survival dengan metode Kaplan-Meier didapatkan 2-YSR dan 3-YSR kanker serviks stadium IIIA sebesar 86% dan 34%. Pada stadium IIIB didapatkan 2-YSR dan 3-YSR sebesar 47% dan 25%.Median survival pada semua kelompok pada penelitian ini adalah 25 bulan.
Simpulan: Jumlah pasien kanker serviks III-IVA yang mendapat kemoterapi dilanjutkan radioterapi selama tahun 2011-2013 sebanyak 77 pasien. Respon terapi komplet pasca radioterapi sebesar 88,3% dan respon terapi inkomplet sebesar 11,7%. Hasil analisis survival didapatkan 2-YSR dan 3-YSR kanker serviks stadium IIIA sebesar 86% dan 34%. Pada stadium IIIB didapatkan 2-YSR dan 3-YSR sebesar 47% dan 25%.
Aziz MF. Gynecological cancer in Indonesia. Journal gynecology oncology. 2009;20(1):8-10.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Inci-dence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer. Available from http://globocan.iarc.fr. 2013.
Andrijono. Kanker serviks uteri. Dalam Sinopsis Kanker Ginekologi. Edisi ke-3. Jakarta: Pustaka Spirit; 2009. p. 59-125.
Eifel PJ, Jhingran A, Brown J, Levenback C, Thames H. Time course and outcome of central recurrence after radiation therapy for carcinoma of the cervix. Int J gynecol Cancer. 2006;16:1106-11.
Achmadi, Tjokroprawiro BA, Suhatno. Karakter-istik Pasien Kanker Serviks 2006-2010 di RSUD dr. Soetomo, Departemen/SMF Obstetri Ginekologi Fakultas Kedokteran Universitas Airlangga. Laporan Hasil Penelitian. 2011. p. 32-69.
Nakano T, Kato S, Ohno T, Tsuji H, Sato S, Fukuhisa K, Arai T. Long-Term Results of High-Dose Rate Intracavitary Brachytherapy for Squamous cell carcinoma of the Uterine Cervix. American Cancer Society. 2005;103(1):92-101.
Anggraeni TD, Nuranna L. Distribution of Age, Stage, and Histopathology of Cervical Cancer: A Retrospective Study on Patients at Dr. Cipto Mangunkusumo Hospital Jakarta 2006-2010. Indones J Obstet Gynecol. 2011;35:21-4.
Kato S, Ohno T, Thephamongkhol K, Chansilpa Y, Cao J, Xu X, Devi CR, Swee TT, Calaguas MJ, de Los Reyes RH, Cho CK, Dung TA, Supriana N, Erawati D, Mizuno H, Nakano T, Tsujii H. Long-term follow-up results of a multi-institutional phase 2 study of concurrent chemoradiation therapy for locally advanced cervical cancer in east and southeast Asia. Int J Radiat Oncol Biol Phys. 2013;87(1):100-5.
Souhami L. Chemoradiation in Locally advanced cervix cancer: a metaanalysis. Int J Clin OncoL. 2011;14(3):233-41.
Schorge JO, et al. Cervical Cancer. In: William Gynecology. 1st Ed. USA: McGraw Hill; 2008. p 646-63.
Parazzini F, La Vecchia C, Negri E, Cecchetti G, Fedele L. Reproductive factors and the risk of invasive and intraepithelial cervical neoplasia. British Journal of Cancer. 1989;59(5):805-9.
Sakata K, Sakurai H, Suzuji Y, Kato S, Ohno T, Tita T, Kataoka M, Eiichi T, Kaneyasu Y, Uno T, Harima Y, Nakano T. Result of concomitant chemoradiation for cervical cancer using high dose rate intracavitary brachytherapy: Study of JRSOG (Japan Oncology Study Group). Acta Oncol. 2008;47:434-41.
Wong LC, Choo YC, Choy D, et al. Long-term follow-up of potentiation of radiotherapy by cisplatinum in advanced cervical cancer. Gynecol Oncol. 1989;35:159-63.
Negi RR, Gupta M, Kumar M, Gupta M.K, Seam R, Rastogi M. Concurrent chemoradiation in locally advanced carcinoma cervix patients. J Cancer Res Ther. 2010;6:159-66.
Yoshida Y, Sato S, Okamura C, Nishino Y, Yajima A. Evaluating the accuracy of uterine cancer screening with the regional cancer registration system. Acta Cytol. 1991;45:157-62.
Sura S, Olshelski M, Rineer J. Effect of histology on survival for patients with invasive non-metastatic cervical cancer: review of the SEER database. Int J Clin Oncol. 2008;5(2):201-6.
Lee JS, Sheets EE, Wenham RM, Duska LR, Coleman RL, Miller DSl. Stage IIB-IV cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol. 2006;84:115-9.
Monk BJ, Tewari KS. Invasive cervical cancer, in Clinical Gynecologic Oncology (editor Creasman WT dan DiSaia PJ). 7th Eds. USA: Mosby Elsevier; 2007. p. 55-124.
Rittiluechai K, Buranawit K, Tanapat Y. The treatment outcome of adenocarcinoma of uterine cervix at Phramongkutklao Hospital. J Med Assoc Thai. 2010;93(6):13-21.
Nag S, Erickson B, Thomadsen B, Orton C, Demanes JD, Petereit D. The American Brachy-therapy Society recommendations for high dose rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2000;48:201-11.
Fyles A, Keane TJ, Barton M, Simm J. The effect of treatment duration in the local control of cervix cancer. Radiother Oncol. 1992;25:273-9.
Girinsky T, Rey A, Roche B, Haie C, Gerbaulet A, Randrianarivvello H. Overall Time Treatment in advanced Cervical Carcinomas: a critical parameter in treatment outcome. Int J Radiat Oncol Biol Phys. 1993;27:1051-6.
Gonzales MA, Lucia GC, Carballo N, Garcia JF, Lapuente F, Rojo A. The current role of neo-adjuvant chemoterapy in the management of cervical carcinoma. Gynecol Oncol. 2008;110:36-40.
Kumar L, Kaushal R, Nandy M. Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized study. Gynecol Oncol. 1998:54:307-15.
Sardi J, Giaroli A, Sananes C. Randomized trial with neoadjuvant chemotherapy in stage IIIb squamous carcinoma cervix uteri: an unexpected therapeutic management. Int J Gynecol Cancer. 1996;6:85-93.
1. Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
2. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
3. The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
